

---

# Initial Coverage Elicera: Cell Therapy Company Under the Radar

Carlsquare Equity Research initiates coverage of Elicera Therapeutics, which develops novel cell therapies for oncology based on the enhancement of validated technologies such as CAR-T and oncolytic viruses. Read the full report [here](#). The Swedish version was published on 13 December 2021.

## About Carlsquare

---

Carlsquare is a Pan-European research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 80+ employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team have an extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Berlin, Copenhagen, Hamburg, London, Munich and Stockholm. [Read more](#)

### Contact

MARKUS AUGUSTSSON  
Head of Equity Research  
[markus.augustsson@carlsquare.com](mailto:markus.augustsson@carlsquare.com)  
+46 (0)76 235 03 20

## Contacts

---

### MARKUS AUGUSTSSON

Head of Equity Research  
[markus.augustsson@carlsquare.com](mailto:markus.augustsson@carlsquare.com)  
+46 (0)76 235 03 20

### JONATAN ANDERSSON

Equity Analyst  
[jonatan.andersson@carlsquare.com](mailto:jonatan.andersson@carlsquare.com)  
+46 (0)70 508 00 51

## Attachments

---

[Initial Coverage Elicera: Cell Therapy Company Under the Radar](#)